120 related articles for article (PubMed ID: 2910559)
1. Fibronectin is unsuitable as a tumor marker in pleural effusions.
Delpuech P; Desch G; Fructus F
Clin Chem; 1989 Jan; 35(1):166-8. PubMed ID: 2910559
[TBL] [Abstract][Full Text] [Related]
2. Fibronectin concentrations in pleural effusions of patients with malignant and non-malignant diseases.
Siri A; Carnemolla B; Raffanti S; Castellani P; Balzano E; Zardi L
Cancer Lett; 1984 Feb; 22(1):1-9. PubMed ID: 6421478
[TBL] [Abstract][Full Text] [Related]
3. Metabonomics by proton nuclear magnetic resonance in human pleural effusions: A route to discriminate between benign and malignant pleural effusions and to target small molecules as potential cancer biomarkers.
Zennaro L; Vanzani P; Nicolè L; Cappellesso R; Fassina A
Cancer Cytopathol; 2017 May; 125(5):341-348. PubMed ID: 28140518
[TBL] [Abstract][Full Text] [Related]
4. The etiology of pleural effusions in an area with high incidence of tuberculosis.
Valdés L; Alvarez D; Valle JM; Pose A; San José E
Chest; 1996 Jan; 109(1):158-62. PubMed ID: 8549179
[TBL] [Abstract][Full Text] [Related]
5. Ischemia modified albumin in the differential diagnosis of pleural effusions.
Dikensoy O; Celik N; Kul S; Gogebakan B; Bayram H; Light RW
Respir Med; 2011 Nov; 105(11):1712-7. PubMed ID: 21843931
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the value of fibronectin as a tumour marker in malignant pleural mesothelioma.
Emri S; Ustündağ Y; Budak T; Karakoca Y; Ozdemir O
Monaldi Arch Chest Dis; 1997 Aug; 52(4):335-8. PubMed ID: 9401361
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of sialic acid in malignant pleural effusions.
Imecik O; Ozer F
Chest; 1992 Dec; 102(6):1819-22. PubMed ID: 1446495
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of soluble interleukin 2 receptor in differentiating tuberculous and carcinomatous pleural effusions.
Chang SC; Hsu YT; Chen YC; Lin CY
Arch Intern Med; 1994 May; 154(10):1097-101. PubMed ID: 8185423
[TBL] [Abstract][Full Text] [Related]
9. A potential role for nitric oxide pathway in tuberculous pleural effusion.
Elgün S; Kaçmaz B; Durak I
Int J Tuberc Lung Dis; 2005 Mar; 9(3):339-43. PubMed ID: 15786901
[TBL] [Abstract][Full Text] [Related]
10. Pentraxin-3: A novel biomarker for discriminating parapneumonic from other exudative effusions.
Ozsu S; Abul Y; Mentese A; Bektas H; Uzun A; Ozlu T; Porcel JM
Respirology; 2013 May; 18(4):657-62. PubMed ID: 23286371
[TBL] [Abstract][Full Text] [Related]
11. Osteopontin is upregulated in malignant and inflammatory pleural effusions.
Moschos C; Porfiridis I; Psallidas I; Kollintza A; Stathopoulos GT; Papiris SA; Roussos C; Kalomenidis I
Respirology; 2009 Jul; 14(5):716-22. PubMed ID: 19476604
[TBL] [Abstract][Full Text] [Related]
12. Soluble receptor-binding cancer antigen expressed on SiSo cells in pleural fluid: a potential diagnostic marker for malignant pleural effusion.
Aoe K; Hiraki A; Maeda T; Murakami T; Yamazaki K; Sugi K; Takeyama H
Chest; 2004 Oct; 126(4):1195-7. PubMed ID: 15486382
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic value of pleural fluid N-terminal pro-brain natriuretic peptide levels in patients with cardiovascular diseases.
Liao H; Na MJ; Dikensoy O; Lane KB; Randal B; Light RW
Respirology; 2008 Jan; 13(1):53-7. PubMed ID: 18197911
[TBL] [Abstract][Full Text] [Related]
14. Clinical utility of pleural fluid NT-pro brain natriuretic peptide (NT-proBNP) in patients with pleural effusions.
Han CH; Choi JE; Chung JH
Intern Med; 2008; 47(19):1669-74. PubMed ID: 18827414
[TBL] [Abstract][Full Text] [Related]
15. Fibronectin in exudative pleural effusions.
Klockars M; Pettersson T; Vartio T; Riska H; Vaheri A
J Clin Pathol; 1982 Jul; 35(7):723-7. PubMed ID: 7096593
[TBL] [Abstract][Full Text] [Related]
16. On the identification of biomarkers for non-small cell lung cancer in serum and pleural effusion.
Rodríguez-Piñeiro AM; Blanco-Prieto S; Sánchez-Otero N; Rodríguez-Berrocal FJ; de la Cadena MP
J Proteomics; 2010 Jun; 73(8):1511-22. PubMed ID: 20230924
[TBL] [Abstract][Full Text] [Related]
17. Expression of YKL-40 and MIP-1a proteins in exudates and transudates: biomarkers for differential diagnosis of pleural effusions? A pilot study.
Adamidi T; Soulitzis N; Neofytou E; Zannetos S; Georgiou A; Benidis K; Papadopoulos A; Siafakas NM; Schiza SE
BMC Pulm Med; 2015 Dec; 15():150. PubMed ID: 26620310
[TBL] [Abstract][Full Text] [Related]
18. Status of lipid peroxidation and antioxidant enzymes in malignant (bronchogenic carcinoma) and non-malignant pleural effusions.
Vanisree AJ; Shyamaladevi CS
Indian J Cancer; 1999; 36(2-4):127-34. PubMed ID: 10921216
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic utility of CYFRA 21-1, carcinoembryonic antigen, CA 125, neuron specific enolase, and squamous cell antigen level determinations in the serum and pleural fluid of patients with pleural effusions.
Ferrer J; Villarino MA; Encabo G; Felip E; Bermejo B; Vilà S; Orriols R
Cancer; 1999 Oct; 86(8):1488-95. PubMed ID: 10526277
[TBL] [Abstract][Full Text] [Related]
20. Elevated survivin is associated with a poor response to chemotherapy and reduced survival in lung cancer with malignant pleural effusions.
Park DS; Hwang KE; Shim H; Kim BR; Choi KH; Park SH; Park SD; Jeong ET; Kim HR
Clin Exp Metastasis; 2012 Feb; 29(2):83-9. PubMed ID: 22045227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
